1. Report Overview

1.1 Why You Should Read This Report

1.2 How This Report Delivers

1.3 Key Questions Answered by This Analytical Report Include:

1.4 Who is This Report For?

1.5 Methodology

1.5.1 Primary Research

1.5.2 Secondary Research

1.5.3 Market Evaluation & Forecasting Methodology

1.6 Frequently Asked Questions (FAQ)

1.7 Associated Visiongain Reports

1.8 About Visiongain

2. Introduction to Anaesthetic Drugs

2.1 What is an Anaesthesia?

2.1.1 Types of Anaesthetics

2.1.1.1 General Anaesthetics

2.1.1.2 Local Anaesthetics

2.1.1.3 Sedation

2.2 What are the Risk and Side Effects of Anaesthesia Drugs?

2.2.1 Localized side effects

2.2.2 General side effects

2.3 Epidemiology of Anaesthetic Drugs

2.4 Humanistic and Economic Burden

2.4.1 Mortality

2.4.2 Morbidity

2.4.3 Economic Impact

3. Introduction to the Global Anaesthesia Drugs Market

4. Leading Drugs in the Global Anaesthesia Drugs Market

4.1 Propofol (Diprivan)

4.2 Sevoflurane (Sojourn, Ultane)

4.3 Remifentanil

4.4 Midazolam

4.5 Lidocaine

4.6 Ropivacaine

5. Market Growth Drivers

5.1 Increasing incidence of surgeries

5.2 Increasing cosmetic surgeries

5.3 Designated ICD-10 Code

5.4 Demand for general anaesthesia drugs

5.5 Increased investment in R&D

5.6 Advancements in medical power supply products

5.7 Rise in Geriatric population

6. Market Challenges

6.1 Healthcare consolidation

6.2 Stringent Regulatory Guidelines

6.3 Paucity of large, prospective and collaborative outcome studies

7. Market Trends

7.1 Advances in modern technologies

7.2 Strategic alliances among key players in the market

7.3 Expansion of healthcare sector in developing countries due to growing investments by major players

7.4 Advancements in drug delivery methods

7.5 Paucity of new drugs to change the practice of operating room Anaesthesia

7.6 Expect improved safety statistics regarding anaesthesia mortality and morbidity

7.7 Rising trend of home healthcare

8. Pipeline Molecules

8.1 Promising Potential Pipeline Molecules

8.1.1 Phase IV Molecules

8.1.1.1 Exparel (Bupivacaine Liposome)

8.1.2 Phase III Molecules

8.1.2.1 Remimazolam (CNS 7056)

8.1.3 Phase I Molecules

8.1.3.1 Cyclopropyl-methoxycarbonyl metomidate (ABP-700)

8.1.3.2 Carboetomidate

8.1.3.3 JM-1232 (-) (MR04A3)

8.1.3.4 Propofol

8.1.3.5 PF0713

8.1.3.6 Fospropofol

8.1.3.7 AZD-3043 (TD4756)

9. Leading Companies in Global Anaesthetic Drugs Market, 2018

9.1. Novartis AG

9.1.1. Company overview

9.1.2. Company snapshot

9.1.3. Operating business segments

9.1.4. Product portfolio

9.1.5. Business performance

9.2. Mylan N.V.

9.2.1. Company overview

9.2.2. Company snapshot

9.2.3. Operating business segments

9.2.4. Product portfolio

9.2.5. Business performance

9.3. Teva Pharmaceuticals Industries Limited AG

9.3.1. Company overview

9.3.2. Company snapshot

9.3.3. Operating business segments

9.3.4. Product portfolio

9.3.5. Business performance

9.4. Merck & Co., Inc.

9.4.1. Company overview

9.4.2. Company snapshot

9.4.3. Operating business segments

9.4.4. Product portfolio

9.4.5. Business performance

9.5. Pacira Pharmaceuticals, Inc.,

9.5.1. Company overview

9.5.2. Company snapshot

9.5.3. Product portfolio

9.5.4. Business performance

9.6. Hikma Pharmaceuticals. plc

9.6.1. Company overview

9.6.2. Company snapshot

9.6.3. Operating business segments

9.6.4. Product portfolio

9.6.5. Business performance

9.7. Glaxosmithkine plc

9.7.1. Company overview

9.7.2. Company snapshot

9.7.3. Operating business segments

9.7.4. Product portfolio

9.7.5. Business performance

9.8. Aspen Pharmacare Holdings Limited

9.8.1. Company overview

9.8.2. Company snapshot

9.8.3. Operating business segments

9.8.4. Product portfolio

9.8.5. Business performance

9.8.6. Key strategic moves and development

9.9. Endo International plc (Endo International)

9.9.1. Company overview

9.9.2. Company snapshot

9.9.3. Operating business segments

9.9.4. Product portfolio

9.9.5. Business performance

9.10. Nuvo Pharmaceuticals

9.10.1. Company overview

9.10.2. Company snapshot

9.10.3. Product portfolio

9.10.4. Business performance

9.11. Lannett

9.11.1. Company overview

9.11.2. Company snapshot

9.11.3. Operating business segment

9.11.4. Product portfolio

9.11.5. Business performance

9.12. Nichi-Iko Pharmaceutical Co., Ltd (Sagent Pharmaceuticals)

9.12.1. Company overview

9.12.2. Company snapshot

9.12.3. Operating business segment

9.12.4. Product portfolio

9.12.5. Business performance

9.13. Jiangsu Hengrui Medicine

9.13.1. Company overview

9.13.2. Company snapshot

9.13.3. Operating business segment

9.13.4. Product portfolio

9.13.5. Business performance

9.14. Mydent International

9.14.1. Company overview

9.14.2. Company snapshot

9.14.3. Operating business segment

9.14.4. Product portfolio

9.14.5. Business performance

9.15. Primex Pharmaceuticals AG

9.15.1. Company overview

9.15.2. Company snapshot

9.15.3. Product portfolio

9.15.4. Business performance

9.16. Fresenius Kabi AG

9.16.1. Company overview

9.16.2. Company snapshot

9.16.3. Operating business segments

9.16.4. Product portfolio

9.16.5. Business performance

9.17. Johnson and Johnson

9.17.1. Company overview

9.17.2. Company snapshot

9.17.3. Operating business segments

9.17.4. Product portfolio

9.17.5. Business performance

9.17.6. Key strategic move and development

9.18. Baxter International Inc.

9.18.1. Company overview

9.18.2. Company snapshot

9.18.3. Operating business segments

9.18.4. Product portfolio

9.18.5. Business performance

9.19. Abbott Laboratories

9.19.1. Company overview

9.19.2. Company snapshot

9.19.3. Operating business segments

9.19.4. Product portfolio

9.19.5. Business performance

9.20. AstraZeneca plc

9.20.1. Company overview

9.20.2. Company snapshot

9.20.3. Operating business segments

9.20.4. Product portfolio

9.20.5. Business performance

9.20.6. Key strategic move and development

9.21. F. Hoffman-La Roche AG

9.21.1. Company overview

9.21.2. Company snapshot

9.21.3. Operating business segments

9.21.4. Product portfolio

9.21.5. Business performance

9.22. AbbVie Inc.

9.22.1. Company overview

9.22.2. Company snapshot

9.22.3. Operating business segments

9.22.4. Product portfolio

9.22.5. Business performance

9.23. B. Braun Melsungen AG

9.23.1. Company overview

9.23.2. Company snapshot

9.23.3. Operating business segments

9.23.4. Product portfolio

9.23.5. Business performance

9.23.6. Key stratregic move and development

9.24. Eisai Co., Ltd.

9.24.1. Company overview

9.24.2. Company snapshot

9.24.3. Operating business segments

9.24.4. Product portfolio

9.24.5. Business performance

9.25. Boehringer Ingelheim GmbH

9.25.1. Company overview

9.25.2. Company snapshot

9.25.3. Operating business segments

9.25.4. Product portfolio

9.25.5. Business performance

10. Conclusions

Visiongain Report Sales Order Form

Associated Visiongain Reports

About Visiongain

Visiongain report evaluation form

List of Tables

Table 2.1 Type of Surgeries performed in 2010 and 2020 (%)

Table 8.1 Active Pipeline Molecules under Development for Anaesthesia Drugs

Table 9.1. Novartis: Company Snapshot

Table 9.2. Novartis: Operating Segments

Table 9.3. Novartis: Product Portfolio

Table 9.4. Mylan N.V.: Company Snapshot

Table 9.5. Mylan N.V.: Operating Segments

Table 9.6. Mylan N.V.: Product Portfolio

Table 9.7. Teva Pharmaceuticals Industries Limited: Company Snapshot

Table 9.8. Teva Pharmaceuticals Industries Limited: Operating Segments

Table 9.9. Teva Pharmaceuticals Industries Limited: Product Portfolio

Table 9.10. Merck: Company Snapshot

Table 9.11. Merck: Operating Segments

Table 9.12. Merck: Product Portfolio

Table 9.13. Pacira: Company Snapshot

Table 9.14. Pacira: Product Portfolio

Table 9.15. Hikma: Company Snapshot

Table 9.16. Hikma: Operating Segments

Table 9.17. Hikma: Product Portfolio

Table 9.18. GSK: Company Snapshot

Table 9.19. GSK: Operating Segments

Table 9.20. GSK: Product Portfolio

Table 9.21. Aspen: Company Snapshot

Table 9.22. Aspen: Main Operating Segments

Table 9.23. Aspen: Product Portfolio

Table 9.24. Endo International: Company Snapshot

Table 9.25. Endo International: Operating Segments

Table 9.26. Endo International: Product Portfolio

Table 9.27. Nuvo: Company Snapshot

Table 9.28. Nuvo: Product Portfolio

Table 9.29. Lannett: Company Snapshot

Table 9.30. Lannett: Product Portfolio

Table 9.31. Nichi: Company Snapshot

Table 9.32. Nichi: Product Portfolio

Table 9.33. Jiangsu: Company Snapshot

Table 9.34. Jiangsu: Product Portfolio

Table 9.35. Mydent: Company Snapshot

Table 9.36. Mydent: Product Portfolio

Table 9.37. Primex: Company Snapshot

Table 9.38. Primex: Product Portfolio

Table 9.39. Fresenius: Company Snapshot

Table 9.40. Fresenius: Operating Segments

Table 9.41. Fresenius: Product Portfolio

Table 9.42. Johnson and Johnson: Company Snapshot

Table 9.43. Johnson and Johnson: Operating Segments

Table 9.44. Johnson and Johnson: Product Portfolio

Table 9.45. Baxter: Company Snapshot

Table 9.46. Baxter: Operating Segments

Table 9.47. Baxter: Product Portfolio

Table 9.48. Abbott: Company Snapshot

Table 9.49. Abbott: Operating Segments

Table 9.50. Abbott: Product Portfolio

Table 9.51. AstraZeneca: Company Snapshot

Table 9.52. AstraZeneca: Product Portfolio

Table 9.53. Roche: Company Snapshot

Table 9.54. Roche: Operating Segments

Table 9.55. Roche: Product Portfolio

Table 9.56. AbbVie: Company Snapshot

Table 9.57. AbbVie: Product Portfolio

Table 9.58. B. Braun: Company Snapshot

Table 9.59. B. Braun: Operating Segments

Table 9.60. B. Braun: Product Portfolio

Table 9.61. Eisai: Company Snapshot

Table 9.62. Eisai: Product Portfolio

Table 9.63. Boehringer: Company Snapshot

Table 9.64. Boehringer: Operating Segments

Table 9.65. Boehringer: Product Portfolio

List of Figures

Figure 9.1. Novartis: Net Sales, 2016–2018 ($Million)

Figure 9.2. Novartis: Revenue Share by Segment, 2018 (%)

Figure 9.3. Novartis: Revenue Share by Geography, 2018 (%)

Figure 9.4. Novartis: SWOT Analysis

Figure 9.5. Mylan N.V.: Net Sales, 2015–2017 ($Million)

Figure 9.6. Mylan N.V.: Revenue Share by Geography, 2017 (%)

Figure 9.7. Mylan N.V.: SWOT Analysis

Figure 9.8. Teva Pharmaceuticals Industries Limited: Net Sales, 2015–2017 ($Million)

Figure 9.9. Teva Pharmaceuticals Industries Limited: Revenue Share by Segment, 2017 (%)

Figure 9.10. Teva Pharmaceuticals Industries Limited: Revenue Share by Geography, 2017 (%)

Figure 9.11. Teva Pharmaceuticals Industries Limited: SWOT Analysis

Figure 9.12. Merck: Net Sales, 2015–2017 ($Million)

Figure 9.13. Merck: Revenue Share by Segment, 2017 (%)

Figure 9.14. Merck: Revenue Share by Geography, 2017 (%)

Figure 9.15. Merck: SWOT Analysis

Figure 9.16. Pacira: Net Sales, 2015–2017 ($Million)

Figure 9.17. Pacira: Revenue Share by Geography, 2017 (%)

Figure 9.18. Pacira: SWOT Analysis

Figure 9.19. Hikma: Net Sales, 2015–2017 ($Million)

Figure 9.20. Hikma: Revenue Share by Geography, 2017 (%)

Figure 9.21. Hikma: SWOT Analysis

Figure 9.22. GSK: Net Sales, 2015–2017 ($Million)

Figure 9.23. GSK: Revenue Share by Segment, 2017 (%)

Figure 9.24. GSK: Revenue Share by Geography, 2017 (%)

Figure 9.25. GSK: SWOT Analysis

Figure 9.26. Aspen: Net Sales, 2017–2018 ($Million)

Figure 9.27. Aspen: Revenue Share by Segment, 2018 (%)

Figure 9.28. Aspen: Revenue Share by Geography, 2018 (%)

Figure 9.29. Aspen: SWOT Analysis

Figure 9.30. Endo International: Net Sales, 2016–2018 ($Million)

Figure 9.31. Endo International: Revenue Share by Segment, 2018 (%)

Figure 9.32. Endo International: SWOT Analysis

Figure 9.33. Nuvo: Net Sales, 2016–2017 ($Million)

Figure 9.34. Nuvo: Revenue Share by Geography, 2017 (%)

Figure 9.35. Nuvo: SWOT Analysis

Figure 9.36. Lannett: Net Sales, 2016–2018 ($Million)

Figure 9.37. Lannett: SWOT Analysis

Figure 9.38. Nichi: Net Sales, 2017–2018 ($Million)

Figure 9.39. Nichi: SWOT Analysis

Figure 9.40. Jiangsu: SWOT Analysis

Figure 9.41. Mydent: SWOT Analysis

Figure 9.42. Primex: SWOT Analysis

Figure 9.43. Fresenius: Net Sales, 2015–2017 ($Million)

Figure 9.44. Fresenius: Revenue Share by Segment, 2017 (%)

Figure 9.45. Fresenius: Revenue Share by Geography, 2017 (%)

Figure 9.46. Fresenius: SWOT Analysis

Figure 9.47. Johnson and Johnson: Net Sales, 2016–2018 ($Million)

Figure 9.48. Johnson and Johnson: Revenue Share by Segment, 2018 (%)

Figure 9.49. Johnson and Johnson: Revenue Share by Geography, 2018 (%)

Figure 9.50. Johnson and Johnson: SWOT Analysis

Figure 9.51. Baxter: Net Sales, 2016–2018 ($Million)

Figure 9.52. Baxter: Revenue Share by Segment, 2018 (%)

Figure 9.53. Baxter: Revenue Share by Geography, 2018 (%)

Figure 9.54. Baxter: SWOT Analysis

Figure 9.55. Abbott: Net Sales, 2016–2018 ($Million)

Figure 9.56. Abbott: Revenue Share by Segment, 2018 (%)

Figure 9.57. Abbott: Revenue Share by Geography, 2018 (%)

Figure 9.58. Abbott: SWOT Analysis

Figure 9.59. AstraZeneca: Net Sales, 2016–2018 ($Million)

Figure 9.60. AstraZeneca: Revenue Share by Segment, 2018 (%)

Figure 9.61. AstraZeneca: Revenue Share by Geography, 2018 (%)

Figure 9.62. AstraZeneca: SWOT Analysis

Figure 9.63. Roche: Net Sales, 2016–2018 ($Million)

Figure 9.64. Roche: Revenue Share by Segment, 2018 (%)

Figure 9.65. Roche: Revenue Share by Geography, 2018 (%)

Figure 9.66. Roche: SWOT Analysis

Figure 9.67. AbbVie: Net Sales, 2016–2018 ($Million)

Figure 9.68. AbbVie: Revenue Share by Segment, 2018 (%)

Figure 9.69. AbbVie: Revenue Share by Geography, 2018 (%)

Figure 9.70. Abbvie: SWOT Analysis

Figure 9.71. B. Braun: Net Sales, 2015–2017 ($Million)

Figure 9.72. B. Braun: Revenue Share by Segment, 2017 (%)

Figure 9.73. B. Braun: Revenue Share by Geography, 2017 (%)

Figure 9.74. B. Braun: SWOT Analysis

Figure 9.75. Eisai: Net Sales, 2016–2018 ($Million)

Figure 9.76. Eisai: Revenue Share by Geography, 2017 (%)

Figure 9.77. Eisai: SWOT Analysis

Figure 9.78. Boehringer: Net Sales, 2016–2017 ($Million)

Figure 9.79. Boehringer: Revenue Share by Segment, 2017 (%)

Figure 9.80. Boehringer: Revenue Share by Geography, 2017 (%)

Figure 9.81. Boehringer: SWOT Analysis

Figure 10.1 Anaesthesia market, by type (% share 2016 & 2028)

Figure 10.2 Anaesthesia market by route of administration (% share 2016 & 2028)